Matches in Wikidata for { <http://www.wikidata.org/entity/Q57074722> ?p ?o ?g. }
Showing items 1 to 55 of
55
with 100 items per page.
- Q57074722 description "article scientifique publié en 2018" @default.
- Q57074722 description "artículu científicu espublizáu en setiembre de 2018" @default.
- Q57074722 description "im September 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q57074722 description "scientific article published on 15 September 2018" @default.
- Q57074722 description "wetenschappelijk artikel" @default.
- Q57074722 description "наукова стаття, опублікована у вересні 2018" @default.
- Q57074722 name "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 name "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 type Item @default.
- Q57074722 label "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 label "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 prefLabel "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 prefLabel "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 P1433 Q57074722-0847E3EC-609E-4191-A628-53673C5CC428 @default.
- Q57074722 P1476 Q57074722-166168F3-0F94-4BFE-9A25-3A39ADAC9836 @default.
- Q57074722 P2093 Q57074722-0D8B9481-9803-41E8-895D-41A5A184A741 @default.
- Q57074722 P2093 Q57074722-502626B4-8E5C-4FD2-BDBB-CBB4EC376A95 @default.
- Q57074722 P2093 Q57074722-68247FD5-B579-4DF0-80DE-14EC47FD097E @default.
- Q57074722 P2093 Q57074722-7C78587D-6650-49F3-8ECB-E36EE362CE7A @default.
- Q57074722 P2093 Q57074722-8258CF15-7207-4CBE-B0CF-C82E1CFD4A11 @default.
- Q57074722 P2093 Q57074722-83B04C14-F51B-4399-8F51-00D017D6E325 @default.
- Q57074722 P2093 Q57074722-9FFB11AD-4A2E-4BAA-A533-65436919B79A @default.
- Q57074722 P2093 Q57074722-C5C17DD9-282F-4187-BF01-056090F4B0D3 @default.
- Q57074722 P2093 Q57074722-D134EEA8-7DF6-4E03-ADB7-7D61C4BD198E @default.
- Q57074722 P2093 Q57074722-FDEC7F80-2546-490B-B21D-0F3B182B934A @default.
- Q57074722 P304 Q57074722-A33E6C11-A067-4939-8C07-C4A0457529BC @default.
- Q57074722 P31 Q57074722-F2D10042-166B-4958-9F20-0B703D32FFC6 @default.
- Q57074722 P356 Q57074722-9443DBF3-B5D9-4D33-BE41-13A1133C6ADC @default.
- Q57074722 P407 Q57074722-9DE4FA60-0A80-457D-8102-72694CE82551 @default.
- Q57074722 P478 Q57074722-5805B565-2F50-4FD0-8261-FE5E8A6CC87D @default.
- Q57074722 P50 Q57074722-05EE6A6F-F528-442F-848F-0EDBF70B9E76 @default.
- Q57074722 P577 Q57074722-0A164A5E-A0F8-4FCD-BDB0-BBC3A87F8CD4 @default.
- Q57074722 P698 Q57074722-96D584AE-3C25-4581-BB47-237559B31A72 @default.
- Q57074722 P356 J.MSARD.2018.09.017 @default.
- Q57074722 P698 30273841 @default.
- Q57074722 P1433 Q26842267 @default.
- Q57074722 P1476 "Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice" @default.
- Q57074722 P2093 "Bhupendra Khatri" @default.
- Q57074722 P2093 "José E Meca-Lallana" @default.
- Q57074722 P2093 "Karthinathan Thangavelu" @default.
- Q57074722 P2093 "Keith R Edwards" @default.
- Q57074722 P2093 "Miqun Robinson" @default.
- Q57074722 P2093 "Myriam Benamor" @default.
- Q57074722 P2093 "Pascal Rufi" @default.
- Q57074722 P2093 "Patricia K Coyle" @default.
- Q57074722 P2093 "Steve Cavalier" @default.
- Q57074722 P2093 "Teri-PRO Trial Group" @default.
- Q57074722 P304 "211-218" @default.
- Q57074722 P31 Q13442814 @default.
- Q57074722 P356 "10.1016/J.MSARD.2018.09.017" @default.
- Q57074722 P407 Q1860 @default.
- Q57074722 P478 "26" @default.
- Q57074722 P50 Q99630149 @default.
- Q57074722 P577 "2018-09-15T00:00:00Z" @default.
- Q57074722 P698 "30273841" @default.